Aberrantly expressed genes in HaCaT keratinocytes chronically exposed to arsenic trioxide

Biomarker Insights

Volumn 6, Issue , 2011, Pages 7-16

  Udensi, Udensi K ^a   Cohly, Hari H P ^a   Graham Evans, Barbara E ^a   Ndebele, Kenneth ^a   Garcia Reyero, Natàlia ^b   Nanduri, Bindu ^c   Tchounwou, Paul B ^a   Isokpehi, Raphael D ^a  

^a Jackson State University   (United States)

^b JACKSON STATE UNIVERSITY   (United States)

^c MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

Anti apoptosis; Anti differentiation; Arsenic trioxide; Chronic exposure; HaCaT cell; Keratinocytes

Indexed keywords

ALDO KETO REDUCTASE FAMILY 1 MEMBER C3; ARSENIC TRIOXIDE; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 1 RECEPTOR TYPE II; OXIDOREDUCTASE; RGS2 PROTEIN; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL CARCINOGENESIS; CHRONIC INFLAMMATION; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; EPIDERMOID TUMOR; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENOTOXICITY; HUMAN; HUMAN CELL; KERATINOCYTE; LONG TERM CARE; LONG TERM EXPOSURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 79952983233     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMI.S6383     Document Type: Article

References (55)

1. Hall M, Chen Y, Ahsan H, et al. Blood arsenic as a biomarker of arsenic exposure: results from a prospective study. Toxicology. 2006;225:225-33
2. Tchounwou PB, Centeno JA, Patlolla AK. Arsenic toxicity, mutagenesis, and carcinogenesis-a health risk assessment and management approach. Mol Cell Biochem. 2004;255:47-55
3. Maloney ME. Arsenic in Dermatology. Dermatol Surg. 1996;22:301-4
4. Meliker JR, Wahl RL, Cameron LL, Nriagu JO. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ Health. 2007;6:4.
5. Mazumder DN, Ghosh A, Majumdar KK, et al. Arsenic contamination of ground water and its health impact on population of district of nadia, west bengal, India. Indian J Community Med. 2010;35:331-8
6. Cheng TJ, Ke DS, Guo HR. The association between arsenic exposure from drinking water and cerebrovascular disease mortality in Taiwan. Water Res. 2010.
7. Argos M, Kalra T, Rathouz PJ, et al. Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study. Lancet. 2010;376:252-8
8. Graham-Evans B, Cohly HH, Yu H, Tchounwou PB. Arsenic-induced genotoxic and cytotoxic effects in human keratinocytes, melanocytes and dendritic cells. Int J Environ Res Public Health. 2004;1:83-9
9. Rea MA, Gregg JP, Qin Q, Phillips MA, Rice RH. Global alteration of gene expression in human keratinocytes by inorganic arsenic. Carcinogenesis. 2003;24:747-56
10. Ding W, Hudson LG, Liu KJ. Inorganic arsenic compounds cause oxidative damage to DNA and protein by inducing ROS and RNS generation in human keratinocytes. Mol Cell Biochem. 2005;279:105-12
11. Rossman TG, Uddin AN, Burns FJ. Evidence that arsenite acts as a cocarcinogen in skin cancer. Toxicol Appl Pharmacol. 2004;198:394-404
12. Schena M. Genome analysis with gene expression microarrays. Bioessays 1996;18:427-431
13. Argos M, Kibriya MG, Parvez F, et al. Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population. Cancer Epidemiol Biomarkers Prev. 2006;15: 1367-75
14. Sasaki A, Oshima Y, Fujimura A. An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. Exp Hematol. 2007;35: 252-62
15. Wang MC, Liu SX, Liu PB. Gene expression profile of multiple myeloma cell line treated by realgar. J Exp Clin Cancer Res. 2006;25:243-9
16. Wlodarczyk BJ, Cabrera RM, Hill DS, et al. Arsenic-induced gene expression changes in the neural tube of folate transport defective mouse embryos. Neurotoxicology. 2006;27:547-57
17. Liu J, Xie Y, Ducharme DM, et al. Global gene expression associated with hepatocarcinogenesis in adult male mice induced by in utero arsenic exposure. Environ Health Perspect. 2006;114:404-11
18. Su PF, Hu YJ, Ho IC, Cheng YM, Lee TC. Distinct gene expression profiles in immortalized human urothelial cells exposed to inorganic arsenite and its methylated trivalent metabolites. Environ Health Perspect. 2006;114: 394-403
19. Bae DS, Hanneman WH, Yang RS, Campain JA. Characterization of gene expression changes associated with MNNG, arsenic, or metal mixture treatment in human keratinocytes: application of cDNA microarray technology. Environ Health Perspect. 2002;110 Suppl 6:931-41
20. Hamadeh HK, Trouba KJ, Amin RP, Afshari CA, Germolec D. Coordination of altered DNA repair and damage pathways in arsenite-exposed keratinocytes. Toxicol Sci. 2002;69:306-16
21. Boukamp P, Petrussevska RT, Breitkreutz D, et al. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol. 1988;106:761-71
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-9
23. Schroeder A, Mueller O, Stocker S, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol. 2006;7:3.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-8
25. Tarcea VG, Weymouth T, Ade A, et al. Michigan molecular interactions r2: from interacting proteins to pathways. Nucleic Acids Res. 2009;37: D642-6
26. Gerling IC, Singh S, Lenchik NI, Marshall DR, Wu J. New data analysis and mining approaches identify unique proteome and transcriptome markers of susceptibility to autoimmune diabetes. Mol Cell Proteomics. 2006;5: 293-305
27. Dallas PB, Gottardo NG, Firth MJ, et al. Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR- how well do they correlate? BMC Genomics. 2005;6:59.
28. Dale M, Nicklin MJ. Interleukin-1 receptor cluster: gene organization of IL1R2, IL1R1, IL1RL2 (IL-1Rrp2), IL1RL1 (T1/ST2), and IL18R1 (IL-1Rrp) on human chromosome 2q. Genomics. 1999;57:177-9
29. Subramaniam S, Stansberg C, Cunningham C. The interleukin 1 receptor family. Dev Comp Immunol. 2004;28:415-28
30. Bossu P, Visconti U, Ruggiero P, et al. Transfected type II interleukin-1 receptor impairs responsiveness of human keratinocytes to interleukin-1. Am J Pathol. 1995;147:1852-61
31. Symons JA, Young PR, Duff GW. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci U S A. 1995;92:1714-8
32. Colotta F, Dower SK, Sims JE, Mantovani A. The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol Today. 1994;15:562-6
33. Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol. 2004;4:378-85
34. Chang SY, Su PF, Lee TC. Ectopic expression of interleukin-1 receptor type II enhances cell migration through activation of the pre-interleukin 1alpha pathway. Cytokine. 2009;45:32-8
35. Siitonen SM, Kononen JT, Helin HJ, et al. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol. 1996;105:394-402
36. Bohm M, Totzeck B, Wieland I. Differences of E-cadherin expression levels and patterns in human lung cancer. Ann Hematol. 1994;68:81-3
37. Kinzler KW, Bigner SH, Bigner DD, et al. Identification of an amplified, highly expressed gene in a human glioma. Science. 1987;236:70-3
38. Saran A. Basal cell carcinoma and the carcinogenic role of aberrant Hedgehog signaling. Future Oncol. 2010;6:1003-14
39. Li X, Deng W, Nail CD, Bailey SK, Kraus MH, Ruppert JM, Lobo-Ruppert SM. Snail induction is an early response to Gli1 that determines the efficiency of epithelial transformation. Oncogene. 2006;25:609-621
40. Karagas MR, Stukel TA, Morris JS, et al. Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study. Am J Epidemiol. 2001;153:559-65
41. Pruitt KD, Tatusova T, Maglott DR. NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res. 2007;35:D61-5
42. Gurney AL, Marsters SA, Huang RM, Pitti RM, Mark DT, Baldwin DT, Gray AM, Dowd AD, Brush AD, Heldens AD, Schow AD, Goddard AD, Wood WI, Baker KP, Godowski PJ, Ashkenazi A, Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol. 1999;9:215-218
43. Baumgartner-Nielsen J, Vestergaard C, Thestrup-Pedersen K, Deleuran M, Deleuran B. Glucocorticoid-induced tumour necrosis factor receptor (GITR) and its ligand (GITRL) in atopic dermatitis. Acta Derm Venereol. 2006; 86:393-8
44. Baltz KM, Krusch M, Baessler T, et al. Neutralization of tumor-derived soluble glucocorticoid-induced TNFR-related protein ligand increases NK cell anti-tumor reactivity. Blood. 2008;112:3735-43
45. Byrne AM, Goleva E, Leung DY. Identification of glucocorticoid-induced TNF receptor-related protein ligand on keratinocytes: ligation by GITR induces keratinocyte chemokine production and augments T-cell proliferation. J Invest Dermatol. 2009;129:2784-94
46. Azzarello JT, Lin HK, Gherezghiher A, et al. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor. Int J Clin Exp Pathol. 2009;3:147-55
47. Fung KM, Samara EN, Wong C, et al. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer. 2006;13:169-180
48. Rizner TL, Smuc T, Rupreht R, Sinkovec J, Penning TM. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol. 2006;248:126-35
49. Emtage P, Vatta P, Arterburn M, et al. IGFL: A secreted family with conserved cysteine residues and similarities to the IGF superfamily. Genomics. 2006;88:513-20
50. Ralph SJ. Arsenic-based antineoplastic drugs and their mechanisms of action. Met Based Drugs. 2008;260146.
51. Kitchin KT, Wallace K. Arsenite binding to synthetic peptides based on the Zn finger region and the estrogen binding region of the human estrogen receptor-alpha. Toxicol Appl Pharmacol. 2005;206:66-72
52. Isokpehi RD, Cohly HHP, Anyanwu MN, et al. Candidate Single Nucleotide Polymorphism Markers for Arsenic Responsiveness of Protein Targets. Bioinformatics and Biology Insights. 2010;4:99-111
53. De VL, Zheng B, Fischer T, Elenko E, Farquhar MG. The regulator of G protein signaling family. Annu Rev Pharmacol Toxicol. 2000;40: 235-71
54. Cao X, Qin J, Xie Y, et al. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene. 2006;25:3719-34
55. Jiang Z, Wang Z, Xu Y, et al. Analysis of RGS2 expression and prognostic significance in stage II and III colorectal cancer. Biosci Rep. 2010;30: 383-90